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Summary A simple colorimetric test, the MTT assay, has been adapted for chemosensitivity testing of human
small cell lung cancer cell lines, and fresh tumour samples. Optimal conditions for clinical chemosensitivity
testing were determined using established SCLC lines. Nineteen different chemotherapeutic agents were tested,
and sixteen of them were found to be cytotoxic in this assay system. The drug sensitivity of a panel of 16
SCLC cell lines was measured and compared. There was very little intraexperiment variation, but the
interexperiment variation was significant. Cell lines which were derived from patients who had not received
chemotherapy at the time the cell line was established were more sensitive (to all but one of the drugs) than
lines derived from treated patients, and the differences were statistically significant for two of the drugs. One
cell line, NCI-H209, which was derived from an untreated patient, stood out as being the most sensitive or
among the most sensitive to all of the drugs tested. Another cell line, H69AR, which is a multidrug resistant
subline of the cell line NCI-H69, was the most resistant to many of the natural product drugs tested. Multiple
drug chemosensitivity testing was performed on eight fresh tumour samples from SCLC patients (five pleural
effusions, one lymph node, and two primary tumours). It was possible to perform chemosensitivity testing on
all of the clinical samples in which sufficient tumour cells were available. The drug sensitivity of the clinical
samples was, in most cases, within the same range as for the cell lines. Since this assay is very rapid and simple
to perform, it may have practical applications in clinical drug sensitivity testing of human tumours.
Lung cancer has become an epidemic in North America,
accounting for over 100,000 deaths annually. Small cell lung
cancer comprises 20 to 25% of these cases. Although the
prognosis in SCLC has improved considerably with the use
of chemotherapy, and response rates are high, only a
minority of patients are cured of the disease. A therapeutic
plateau has now been reached, and new approaches are
required to improve the results of treatment with currently
available chemotherapeutic agents.
The results of empiric selection of chemotherapeutic drugs
for treatment of individual patients with lung cancer could be
improved by the use of a practical predictive assay of drug
sensitivity. To aid in making therapeutic decisions, such an
assay should be simple, rapid, inexpensive, and available to
most patients. The clonogenic assay of Hamburger and
Salmon (1977) has been used for predictive chemosensitivity
testing, and positive clinical correlations have been found in
a variety of tumour types (Browman et al., 1983; Park et al.,
1980; Von Hoff et al., 1981), including lung cancer (Shimizu
et al., 1981). However, the assay is highly labour-intensive,
results are not available for 2-3 weeks, and numerous tech-
nical and theoretical problems remain (Browman et al., 1986;
Selby et al., 1983; Twentyman, 1985).
As a result, there has been renewed interest in short term
assays of drug sensitivity (Weisenthal & Lippman, 1985). The
MTT assay is a simple colorimetric test of cell proliferation
and survival which was developed by Mosmann (1983) and
adapted by Cole (1986) and others for measuring chemosen-
sitivity of human lung cancer cell lines. A number of groups
have used this assay for drug sensitivity testing of human cell
lines (Carmichael et al., 1987, 1988; Finlay et al., 1986; Park
et al., 1987; Twentyman & Luscombe, 1987), and it is now
being used for screening new anticancer agents (Alley et al.,
1988, Ruben & Neubauer, 1987). It has also been used for
chemosensitivity testing of fresh human leukaemia samples
(Campling et al., 1988; Pieters et al., 1989; Twentyman et al.,
1989). In most instances, there is a close correlation between
results of drug sensitivity testing using this assay and the
clonogenic assay (Carmichael et al., 1987; Wasserman &
Twentyman, 1988). Because of its simplicity, the MTT assay
has the potential to overcome a number of the problems
encountered with other chemosensitivity assays which have
prevented their routine use in clinical practice.
The purpose of the present investigation was to adapt the
MTT assay for chemosensitivity testing of fresh human
SCLC tumour samples. Initial experiments were performed
using human SCLC cell lines in order to determine appropri-
ate seeding cell densities, drug concentrations and drug
incubation times. Once optimal conditions were determined,
the chemosensitivity of a panel of SCLC cell lines was
measured and compared. In addition, eight fresh tumour
samples from SCLC patients were tested for their sensitivity
to a broad range of chemotherapeutic agents. Although the
MTT assay has been used extensively for chemosensitivity
testing of human tumour cell lines, to the best of our
knowledge, there have been no previous published reports of
its use for chemosensitivity testing of human solid tumours.
Materials and methods
Cell lines
The cell lines used for this study are described in Table I.
The source of the lines, and the treatment and response
histories of the patients from whom the lines were derived
are indicated in this table. Many of the lines were established
in this laboratory and will be described in detail in a future
publication. The cell lines NCI-H69, NCI-H128, and NCI-
H209 were provided by Dr J. Minna, NCI-Navy Medical
Oncology Branch, National Cancer Institute, Bethesda,
Maryland (Carney et al., 1985). H69AR is a multidrug resis-
tant variant of NCI-H69, which was selected in Adriamycin
(Mirski et al., 1987). Cell line Mar was a gift from Prof. A.
Neville, Ludwig Institute for Cancer Research, London, UK
(Ibson et al., 1987). Cell line SHP-77, established by Fisher
and Paulson (1978), was obtained from Dr Jorgen Fogh,
Sloan Kettering Institute for Cancer Research, New York.
Cell lines RG-1 and MM-1 were established by Dr W.E.C.
Bradley, Institut du Cancer de Montreal, and characterised
in this laboratory. All of the lines are SCLC cell lines with
the possible exception of three lines, BK-T, HG-E and SHP-
77, in which there is some controversy as to the histologic
diagnosis. BK-T is either SCLC or an atypical carcinoid
tumour, and HG-E is either an intermediate cell variant of
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Table I Cell lines used for chemosensitivity studies
Line Clinicalhistory Source (reference)
AD-A Needle aspirate ofsubcutaneous lumpin apatient who hadprogressive Thislaboratory
disease aftermulti-agent chemotherapy.
BK-T Primary tumour resected from apatientwhosubsequently received This laboratory
combination chemotherapy and is aliveand well several years later.
LG-T Lymph node biopsy from apatientwith limited SCLC who Thislaboratory
subsequently had acomplete response tochemotherapy (but has since
recurred).
HG-E Pleural effusion from apatient with extensive metastatic disease who This laboratory
died shortly afterwards and neverreceived chemotherapy.
JO-E Pleural effusion from apatient who had recurred following acomplete This laboratory
response tochemotherapy.
WL-E Pleural effusion from apatient who had been treated with This laboratory
chemotherapywith aminimal response.
JN-M Bonemarrow from apatient with otherwise limited SCLC, who This laboratory
subsequently had apartial response tochemotherapy and
radiotherapy.
SH-A Needle aspirate ofa supraclavicular node from apatientwho had This laboratory
previously had acomplete response tochemotherapy, and
subsequently responded to furtherchemotherapy.
RG-I Pericardial effusion from apatient who had recurred after W.E.C. Bradley. Characterized in
chemotherapy forlimited stage SCLC. this laboratory
MM-I Pleural effusion from apatient who had recurrentdiseaseafter W.E.C. Bradley. Characterized in
combination chemotherapy forlimited stage SCLC. this laboratory
NCI-H69 Pleural effusion from a patient who had receivedchemotherapy. J.D. Minna(Carney etal., 1985)
H69AR Multidrug-resistant variant ofNCI-H69 selected in S.P.C. Cole(Mirski, Gerlach &
adriamycin. Cole, 1987)
NCI-H128 Pleural effusion from a patient who had receivedchemotherapy. J.D. Minna(Carney etal., 1985)
NCI-H209 Bone marrow from an untreated patient. J.D. Minna(Carney etal., 1985)
Mar Derived from an untreated patient. A. Neville (Ibson etal., 1987)
SHP-77 Primary tumour from apatient who had not received chemotherapy. Fisher & Paulson (Fisher&
Paulson, 1978) (obtained fromJ.
Fogh)
SCLC or large cell anaplastic carcinoma (Campling et al.,
submitted). SHP-77 is considered a large cell variant of
SCLC (Fisher & Paulson, 1978).
All cell lines were maintained at 37°C in a humidified
atmosphere with 5% CO2. The medium used was RPMI 1640
medium supplemented with hydrocortisone (10nM, Sigma),
insulin (10 Lg ml1', Sigma), transferrin (10ltg ml- ', Sigma),
estradiol (10 nM, Sigma), and sodium selenite (30 nM)
(HITES medium) supplemented with 2.5% FBS (SS-HITES).
Antibiotics were not routinely used. The cells were fed or
subcultured at least once weekly.
Fresh tumour samples
Seventeen clinical samples from SCLC patients were received
in the laboratory. These specimens were taken for diagnostic
or therapeutic indications, and samples were sent for drug
sensitivity testing with the informed consent of the patients.
The type and quantity of the samples are shown in Table II.
The solid tumour specimens were disaggregated using a wire
mesh. The effusion samples were centrifuged and the cells
washed in RPMI medium. For all of the fresh tumour sam-
ples, viable cells were separated from red cells and debris
using a Ficoll Hypaque density gradient, and the cells were
washed and resuspended in SS-HITES supplemented with
50jg ml-' of gentamycin. Cytocentrifuge preparations were
made from each of the specimens to determine the propor-
tion of tumour cells present.
Drug sensitivity studies were performed on eight of these
samples (numbers 1, 3, 7, 8, 13, 14, 16 and 17). Sample I
consisted of pleural fluid from a previously untreated patient
with extensive SCLC. The patient died a few days after the
first chemotherapy treatment. Sample 3 was a supraclavicular
lymph node biopsy taken from a patient with a lung mass.
The biopsy revealed a diagnosis of SCLC. The patient was
subsequently treated with radiotherapy, and chemotherapy
Table II Clinical samples from SCLC patients
Sample Typeof Volume of Cell Numberof number sample* samplet countt Cytology drugs tested
I PE 200 ml 2 x 107 Almostentirely SCLC 9 2 PerE 150 ml <106 Mostlylymphocytes, occasional cells suspicious ofSCLC
3 LN 1.5cm3 3.4 x 107 Almostentirely SCLC 11 4 PE 200 ml <106 Mostlylymphocytes
S PE 400 ml < 106 Mostly lymphocytes
6 PE 100 ml < 106 Mostly lymphocytes
7 PE I000 ml 2.6 x 107 70% ofcells SCLC, restlymphocytes and occasional mesothelial cells 9 8 PE 500 ml 5.6 x 107 Predominantly SCLC, occasionallymphocytes and mesothelial cells 9 9 PE 60 ml <106 Occasional clusterofSCLC
10 PE 500 ml <106 Mostlylymphocytes
11 PE 230 ml 1.0 x 106 Lymphocytes outnumbered SCLC 5:1
12 PE 2150 ml <106 Mostlylymphocytes, occasional clumps ofSCLC
13 PE 1000 ml 4.8 x 107 AlmostentirelySCLC 12 14 PE 450 ml 5.7 x 107 AlmostentirelySCLC 10 15 PE 45 ml <106 Mostlylymphocytes
16 Prim 2.0cm3 2.4 x 107 Almostentirely SCLC 11 17 Prim 2.5cm3 3.4 x 107 Almostentirely SCLC 11
*Pleural effusion, PE; pericardial effusion, Per E; lymph node, LN; primary tumour, Prim. tPreparation of the samples is outlined in the Materials and methods section. ITotal number of SCLC cells in the sample.CHEMOSENSITIVITY TESTING OF SMALL CELL LUNG CANCER 77
(cyclophosphamide, adriamycin and vincristine (CAV)), and
had a minor response. Sample 7 consisted of pleural fluid
from a patient with SCLC who had progressed after an
initial response to chemotherapy (CAV alternating with VP-
16 and cisplatin (VP/CP)). Sample 8 was pleural fluid from a
patient with extensive SCLC who had progressed on
chemotherapy (one cycle of CAV followed by one cycle of
VP/CP). The patient subsequently had a partial response to
radiotherapy and further chemotherapy. Sample 13 consisted
of pleural fluid from a patient with extensive SCLC who had
progressed after one cycle of chemotherapy (CAV). The
patient refused further therapy. Sample 14 was pleural fluid
from a patient who had developed progressive disease several
months after a partial response to six cycles ofchemotherapy
(CAV alternating with VP/CP). Samples 16 and 17 were
resected primary tumours from patients with limited SCLC.
Both patients are currently receiving chemotherapy.
Drugs
Most of the drugs were obtained from the Kingston General
Hospital Pharmacy, already dissolved in the appropriate
diluent for infusion. These drugs included Adriamycin,
epirubicin, daunomycin, menogaril, mitoxantrone, VP-16,
VM-26, vincristine, vinblastine, cisplatin, carboplatin,
mitomycin C, m-amsacrine, nitrogen mustard, and metho-
trexate. Procarbazine and CCNU were obtained in capsule
form, from the same source, and the contents of the capsule
were dissolved in sterile medium. Melphalan was obtained
from Sigma, and was dissolved in acidified ethanol. 4-
Hydroperoxycyclophosphamide was obtained from Dr M.
Colvin, The Johns Hopkins Hospital, Baltimore, MD. Most
of the drugs were stored at - 20°C in aliquots at 20 times the
desired final concentration. Cisplatin, VP-16, VM-26, and
mitoxantrone were stored at room temperature, and vincris-
tine was stored at 4°C.
MTT assay
Cell preparation All of the cell lines grew as floating aggre-
gates with the exception of SHP-77, which was loosely
adherent to plastic. To disaggregate the cells, they were
centrifuged, resuspended, and drawn up and down three
times through a 21 gauge needle. Cells were resuspended in
SS-HITES, and dispensed into 96 well microtitre plates (Lin-
bro 76-032-05) at the desired cell density using a 100jil
multichannel pipette.
Cell density The effect of seeding cell densities on absorb-
ance values was determined over a range of cell densities on
one of the cell lines (BK-T), and on one of the clinical
samples which consisted entirely of tumour cells (sample 13).
To determine the relative contribution to the absorbance
readings of contaminating normal cells which may be present
in clinical tumour samples, fresh human peripheral blood
mononuclear cells, obtained by Ficoll Hypaque density
gradient centrifugation, were tested in the same manner. Cells
were plated in duplicate 96 well microtitre plates at densities
ranging from 103 to 5 x 105 cells per well, and each cell
density was tested in four to eight wells. Absorbances were
determined (after addition of MTT (see below)) either
immediately or after 48 h. For all comparative chemosen-
sitivity studies with cell lines and with fresh tumour samples,
a cell density of 105 cells/well was used.
Chemosensitivity studies
Drug dilutions Drugs were added approximately 16 h after
the cells were plated, diluted in SS-HITES to twice the
desired final concentration. One hundred microlitres of drug
solution were added to wells containing 100 jlI of cell suspen-
sion. Serial dilutions of drug were tested in concentrations
ranging from 100Ag ml-' to 0.Iig ml-'. Controls included
wells with cells without drug, and wells with the highest
concentrations of drug without cells. Each drug concentra-
tion was tested in quadruplicate.
Chemosensitivity assay duration Using the cell line NCI-
H69, varying durations of drug exposure were tested, ranging
from I to 3 days. The following drugs were tested: Adria-
mycin, cisplatin, menogaril, mitoxantrone, nitrogen mustard
and VP-16. For comparative chemosensitivity studies, a drug
exposure time of 48 h was used.
Effect of cell density on cytotoxicity It is difficult to obtain
highly accurate cell counts using SCLC cell lines because the
cells often form tight aggregates. Because of concerns that
drug induced cytotoxicity might be affected by the seeding
cell density (Chambers et al., 1984; Ohnuma et al., 1986), the
cytotoxicity of several drugs was compared at different cell
densities. Cell lines BK-T and NCI-H69 were used for these
studies. Plates were set up at densities of 6 x 104, 8 x 104, 105
and 2 x 105 cells per well. Serial dilutions of the following
drugs were tested at each cell density: adriamycin, cisplatin,
daunomycin, epirubicin, mitomycin C, nitrogen mustard,
vinblastine, VP-16, and 4-hydroperoxycyclophosphamide.
Comparative chemosensitivity studies Dose response curves
were generated for the 16 cell lines with each of the 16 active
drugs. A standard cell density of I0 cells per well, and a
drug incubation time of 48 h were used for these studies.
Each of the cell lines was tested at least once with each of the
drugs, and many of the lines were tested on multiple
occasions, up to seven times with the same drug. Eight of the
fresh clinical samples had sufficient tumour cells for multiple
drug chemosensitivity testing, and nine to twelve drugs were
tested on each of these eight samples.
Development ofthe plates
MTT (Sigma) was dissolved in PBS to a concentration of
2 mg ml-'. After the desired incubation time with drug,
100 jI of medium was removed and 25 jl of MTT solution
was added to each well. After 6 h incubation at 37°C, 100,d
of I N HCl:isopropanol (1:24) was added to each well and
mixed vigorously using a multichannel pipette. To increase
the solubilisation of the formazan crystals, the plates were
then incubated at 37°C for I h as described (Campling et al.,
1988). Absorbance values at 570 nm were determined on a
Dynatech MR600 microtitre plate reader.
Data analysis andstatistics
Data were entered on a Digital Microvax II minicomputer
using a form-based system, stored in a relational database
(Vax Rdb), and retrieved with a simple query language,
Datatrieve. Custom software was used to calculate means
and standard deviations for each drug concentration and
generate dose response curves for each drug, to be displayed
on either a graphics terminal or a laser printer for hardcopy.
The dose response curves were normalised so that the
baseline absorbance with no added drug was given a value of
one. Two summary statistics were used for describing and
comparing the dose response curves, namely the IC50 (the
concentration of drug which caused 50% reduction in absor-
bance compared to baseline values), and the area under the
dose response curve (AUC). The IC-% was derived by fitting a
fourth degree polynomial regression to the data, and the
AUC was calculated between drug concentrations of 0 and
100jig ml-' by the trapezoidal method (Moon 1980). The
same concentration range was used for all of the drugs.
The intraexperiment variation (or repeatability) of the
assay was assessed by determining the standard deviation of
the AUC. This was done by generating a family of dose
response curves by connecting the four data points at each
drug concentration to each of the four data points at all of
the other drug concentrations. The AUC for each of these
curves was determined, and the mean AUC and standard
deviation calculated. The interexperiment variation (or re-
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mean and standard deviation for the AUC of repeated tests
with the same drug and cell line. All statistical analyses were
performed using the SAS statistical package (SAS Institute
Inc., 1985).
Clinical correlation
The cell lines were classified according to the treatment status
of the patients from whom the lines were established. This
information is provided in Table I. It can be seen that cell
lines BK-T, LG-T, HG-E, NCI-H209, Mar, and SHP-77
were derived from untreated patients, and cell lines AD-A,
JO-E, WL-E, JN-M, SH-A, RG-1, MM-1, NCI-H69, and
NCI-H128 were derived from treated patients. The cell line
H69AR was excluded from this analysis, since it had under-
gone in vitro selection for drug resistance. The mean AUC
for all of the cell lines from untreated patients was deter-
mined for each of the drugs and compared to the mean AUC
for the cell lines from treated patients. Analysis of variance
was applied to determine the statistical significance of the
differences between cell lines from untreated patients and
from treated patients for each of the drugs. A similar com-
parison was made for the clinical samples.
Results
Sixteen of the 19 drugs tested were cytotoxic in this assay.
Procarbazine, methotrexate, and CCNU did not cause
cytotoxicity and the reasons for this are unclear at the pre-
sent time. It was possible to perform chemosensitivity testing
with multiple drugs on all of the cell lines and on eight of the
clinical samples (all of the samples in which sufficient tumour
cells were obtained).
Cell density
The relationship of cell density to absorbance is shown in
Figure 1. It can be seen that there is a linear relationship
over the range of densities tested. The absorbance of this
particular clinical sample was greater than that of the cell
line, BK-T. However, as discussed below, the baseline absor-
bances of the clinical samples were quite variable. The absor-
bance of the peripheral blood mononuclear cells was much
less than either the tumour sample or the cell line at all cell
densities. For example, at 105 cells per well, the absorbance
of the lymphocytes was approximately one tenth that of the
fresh tumour sample. In the experiment shown, MTT was
added immediately after the cells had been plated. In a
second experiment, MTT was added after 48 h incubation,
and the results were essentially the same (not shown).
Assay duration
The effects of different drug exposure times were determined,
and the results with six different drugs are shown in Figure 2.
On the basis of this data and other results with clinical
samples (Campling et al., 1988), a drug incubation time of
two days was selected for comparative chemosensitivity
studies. This exposure time was sufficient to produce cyto-
toxicity with the 16 active drugs tested, and short enough to
minimise the variable effects of cell proliferation and cell
death over the assay period, an important consideration
when the assay is applied to fresh tumour samples. For the
three drugs which were not cytotoxic in this assay, namely
procarbazine, methotrexate and CCNU, cytotoxicity was not
seen even with drug incubation times of up to 1 week.
Effect ofcell density on cytotoxicity
At the cell densities tested (6 x 104, 8 x 104, 105, and 2 x 105
cells/well), there were no significant differences in cytotoxicity
with the nine drugs tested (data not shown). Because of the
difficulty in obtaining an accurate cell count with SCLC
samples due to cell clumping, it is important to know that
the assay is reproducible over this range of cell densities.
Data analysis
The IC50 and AUC were used to summarise and compare the
dose response curves. It was not always possible to determine
the IC50 since in some cases there was very little cytotoxicity
even at the highest drug concentrations, and in other cases
there was greater than 50% cytotoxicity at the lowest drug
concentrations. In a few instances, the IC50 was poorly
estimated since there was stimulation of growth at the lowest
drug concentrations (Vichi & Tritton, 1989). For these reasons,
the AUC has been used to express the cytotoxicity data. The
details of the statistical analysis are presented elsewhere (Lam
et al., 1989). As outlined in this paper, there was a linear
relationship between the log of the IC50 and the AUC.
Comparative chemosensitivity studies
The results of comparative chemosensitivity testing of the 16
cell lines with the 16 different drugs are shown in Figure 3.
The cell lines have been rank ordered according to AUC.
When a particular cell line has been tested more than once
with the same drug, the standard deviations for repeat deter-
minations are shown, and the number of times the experi-
ment has been repeated is indicated as a measure of inter-
experiment variation, or reproducibility of the assay. The
intraexperiment variation of the AUC's was quite low, with
coefficients of variation generally less than 4%.
It can be seen that one particular cell line, NCI-H209,
stood out as being the most sensitive, or among the most
sensitive to all of the drugs tested. This included drugs which
are part of the multidrug resistance phenotype (Gerlach et
al., 1986), such as the anthracyclines and vinca alkaloids, as
well as other drugs such as alkylating agents and platinum
analogues. This cell line was tested on multiple occasions
from 1986 to 1989, and the pattern of sensitivity has
remained stable.
Another cell line, H69AR, which was selected for resis-
tance to adriamycin and is known to be multidrug resistant
(Mirski et al., 1987), was the most resistant to many of the
natural product drugs, including Adriamycin, epirubicin, vinblastine, vincristine, and VP-16, and was among the most
resistant to daunomycin and menogaril. It is interesting that
this line was resistant to one of the alkylating agents tested, namely melphalan. Surprisingly, it did not appear to be
resistant to mitoxantrone or VM-26, and it was not resistant
to amsacrine, cisplatin, carboplatin, mitomycin C, nitrogen
mustard, or 4-hydroperoxycyclophosphamide. Cell line NCI-
H69, the parent line from which H69AR was derived, and
which was established from a patient who had received
chemotherapy, was not outstandingly sensitive or resistant to
the majority of the 16 drugs tested.
Fresh tumour samples
As outlined in Table II, 17 samples from SCLC patients were
received in the laboratory, and there were sufficient tumour
cells for multiple drug chemosensitivity testing in eight of these samples. The cytological composition of the samples is
shown in this table. It can be seen that all three of the solid
tumour samples consisted of virtually a pure population of
tumour cells in adequate numbers. There were sufficient
tumour cells in only five of the 14 effusion samples. In six of
the effusion samples there were no definite malignant cells
present. The majority of the contaminating cells in these
effusions were lymphocytes. Although there were occasional
macrophages and mesothelial cells in some of the samples, they did not make up a significant percentage of the total cell population. Thus, the results presented here represent the
drug sensitivity of tumour cells, and not that of non malig-
nant cells in the specimens.
The baseline absorbances for the clinical samples (i.e.
absorbance of untreated control wells plated at 105 cells/well, with MTT added after 2 days) were as follows: Sample 1:CHEMOSENSITIVITY TESTING OF SMALL CELL LUNG CANCER 79
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Figure 3 AUC's for the 16 SCLC cell lines tested with 16 drugs. In those cases in which the experiment has been performed more
than once, standard deviations are indicated. The number of determinations is indicated in parentheses underneath the name of the
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Table III AUC's for clinical samples from SCLC patients *untreated, ttreated at time of testing. (N.T. = not tested)
Rangeforcell Areaunderdoseresponse curve
Drug lines Sample * Sample3* Sample 7t Sample8t Sample 13t Sample14t Sample16* Sample17*
Adriamycin 7.4-47.0 13.2 ± 2.0 34.1 ± 2.8 23.7 ± 2.2 15.3 ± 0.7 22.3 ± 0.6 26.7 ± 1.2 25.9 ± 1.6 15.9 ± 0.6
Carboplatin 22.5-86.5 53.2 + 3.0 56.4 ± 3.1 86.9 ± 3.3 78.0 ± 2.5 95.5 ± 2.2 82.5 ± 3.0 83.0± 5.1 88.9 ± 1.2
Cisplatin 7.5-43.0 12.9 ± 2.5 N.T. 44.9 ± 0.9 10.8 ± 0.3 50.9 + 1.3 28.9± 0.7 29.6± 1.7 19.3 ± 2.7
Epirubicin 2.6-57.0 28.1 ± 2.4 36.5 + 2.7 17.8 ± 0.3 8.3 ± 0.4 13.3 ± 0.6 23.3 ± 0.5 17.7 ± 1.6 15.5 ± 1.2
Menogaril 3.5-17.3 18.2 2.8 18.7 2.1 N.T. N.T. 7.7 0.3 N.T. 11.8 1.6 11.8 0.4
Mitoxantrone 14.8-28.1 36.6 ± 8.0 9.2 ± 3.3 18.4 ± 1.1 8.2 ± 0.6 10.3 ± 0.5 23.4± 1.1 29.5 ± 1.8 17.0± 1.6
Nitrogenmustard 5.9-29.8 8.4 ± 0.6 28.1 2.6 N.T. N.T. 13.8 ± 0.3 28.3 +1.0 18.7 +1.5 15.6± 0.4
Vincristine 30.7-84.1 54.1 ± 3.4 68.3 ± 9.2 60.0 ± 2.0 84.9 ± 2.2 55.4± 1.0 72.0± 1.6 59.7 ± 2.8 68.5 ± 2.0
VM26 5.0-32.9 N.T. 17.5 ± 2.0 N.T. 28.0 ± 1.6 9.4± 0.4 27.0±+0.9 34.0 ± 1.6 45.8 ± 1.9
VP16 33.0-86.6 53.9 ± 1.6 54.3 4.0 81.7 2.6 120.6 4.7 57.9 1.0 95.6 ±2.8 59.4 2.2 67.3 2.5
4H-Cyclophosphamide 11.1-55.2 N.T. 25.0 3.1 50.9 0.7 90.9 1.5 74.9 2.2 92.2 ± 3.0 30.1 ± 1.0 88.1 2.4
The clinical history of the patients in whom drug sensitivity testing was performed is indicated in the Materials and methods section.
Table IV Comparison of mean AUC of cell lines derived from untreated vs treated patients
Comparison of cell lines from untreated vs treated patients
Drug Mean AUC- untreated Mean AUC- treated P value
Adriamycin 24.3 28.2 0.30
Amsacrine 13.4 19.2 0.13
Carboplatin 50.5 63.0 0.05*
Cisplatin 25.9 29.4 0.32
4H-Cyclophosphamide 27.3 30.0 0.67
Daunomycin 9.7 16.2 0.17
Epirubicin 19.1 21.8 0.48
Melphalan 30.8 35.0 0.38
Menogaril 9.8 11.1 0.45
Mitomycin C 24.9 28.6 0.48
Mitoxantrone 18.4 24.0 0.07
Nitrogen mustard 12.7 18.5 0.02*
Vinblastine 35.6 41.7 0.45
Vincristine 56.9 49.3 0.28
VM26 20.3 24.3 0.53
VP16 42.5 50.4 0.18
*Indicates statistical significance.
were only four patients in each group, and it was not possi-
ble to make any comment about the response status of the
untreated patients, since one of them died before treatment
could be given, two of them had their tumours resected, and
were thus not assessable for response to chemotherapy, and
one had a very minimal response to subsequent treatment.
Discussion
The use of a predictive assay of drug sensitivity could have
an impact on the management of patients with lung cancer.
In fact, a recently reported clinical trial in extensive SCLC
comparing empiric selection of chemotherapy to selection
based on the results of chemosensitivity testing suggests that
response rates may be improved by this approach (Gazdar et
al., 1990). The clonogenic assay has proven to be of limited
practical use since drug sensitivity testing can be performed
in only a minority of lung cancer cases (De Vries et al., 1987;
Kitten et al., 1982), although improved culture techniques
have resulted in higher success rates (Kanzawa et al., 1987).
The major advantages of the MTT assay are its speed and
simplicity. Because most steps are automated, it is possible to
test multiple drugs, each at several concentrations. The
automated data analysis is essential in view of the large
amounts of data that can be generated. Since results are
available within 3 days, such information may be of value in
clinical therapy. Furthermore, a short assay duration will
minimise the variable effects of cell proliferation and cell
death over the assay period.
In order to perform testing of multiple drugs, relatively
large numbers of cells are required. However, the test as we
describe it requires no more cells than the clonogenic assay,
or the DiSC assay of Weisenthal (Weisenthal et al., 1983),
which, when applied to lung cancer, requires 2 x 105 cells per
data point (De Vries et al., 1987).
It has been argued that the potential application of this
assay to clinical chemosensitivity testing is limited (Car-
michael et al., 1987; 1988). In fact, it would likely not be
possible to perform the assay as described by others in the
majority of clinical samples, because of the low seeding cell
densities commonly used. The importance of having the cells
in exponential growth phase during the assay period has been
emphasised. However, the majority of samples derived from
patients will not be growing exponentially.
Carmichael et al. (1987) reported high coefficients of varia-
tion (15% on octuplicate determinations) when the MTT
assay was used for sensitivity testing of cell lines that grow in
suspension, such as SCLC. However, in the present study we
found that the coefficients of variation on quadruplicate
determinations were usually less than 4%. There are a
number of possible explanations for this discrepancy. In the
Carmichael study, DMSO was used to solubilise the for-
mazan crystals. We have found that DMSO increased absor-
bance values, but also increased the intraexperimental varia-
tion. Futhermore, when DMSO is used, most of the medium
must be removed from the wells prior to the addition of
DMSO. It would be difficult to avoid removing some cells in
the process, and this could contribute to the higher standard
deviations observed. Finally, since low seeding cell densities
are used, there could be differential cell growth in the wells
during the assay period, thus increasing the coefficients of
variation.
Although the intraexperiment variation reported here is
less than that of other investigators, the interexperiment
variation is a significant problem which needs to be con-
sidered when interpreting chemosensitivity results, and may
be a limiting factor if the assay is to be applied in the clinical
setting. We believe that the interassay variability is more
likely to be a function of the cell lines than an inherent
problem with the MTT assay. The cell lines were tested
repeatedly over a period of 3 years. While no trends towards
either increasing or decreasing drug sensitivity were noted
over this period of time, it is possible that the drug sensitivity82 B.G. CAMPLING et al.
may have been unstable. Other potential causes of interassay
variation are differences in growth rates between the cell
lines, and variations in cell cycle parameters which cannot be
completely controlled. These problems are more likely to
produce significant artifacts when longer assay durations are
employed. This was one of the considerations in our selection
of a short drug incubation time. It should also be noted that
it is much easier to quantitate interexperimental variation
using the MTT assay than with other assays of cytotoxicity
because of the ease with which multiple repeat assays can be
performed.
Contamination of tumour specimens with infiltrating non-
malignant cells is a potential problem with the MTT assay,
as with most other short-term assays of cytotoxicity. How-
ever, the clinical samples that we tested had very minimal
contamination with non-tumour cells. The predominant non-
malignant cells in the samples received to date have been
lymphocytes. Furthermore, we have shown that peripheral
blood mononuclear cells (which include lymphocytes) reduce
the tetrazolium dye much less than SCLC tumour cells. Thus,
the chemosensitivity results of the eight clinical samples pre-
sented here represent the drug sensitivity of tumour cells.
Overgrowth of fibroblasts has not occurred with the assay
described here, likely because of the short drug incubation
time, and the use of selective medium. Contamination of
tumour samples with non-malignant cells may prove to be a
more significant problem with other tumour types. However,
if large numbers of contaminating non-malignant cells are
present, it should be possible to remove them using a variety
of cell separation procedures.
The MTT assay described here is conceptually somewhat
different than that developed by Cole (1986) for chemosen-
sitivity testing of human lung cancer cell lines. Cole's method
uses lower seeding cell densities and a longer drug incubation
period. Thus, it measures a combination of drug-induced
cytotoxicity and inhibition of cell growth. In the present
study, a shorter drug incubation time was used, measuring
primarily cytotoxicity. Tumour samples obtained directly
from patients cannot necessarily be expected to proliferate in
tissue culture.
The relative resistance to natural product drugs of H69AR
compared to its parent cell line NCI-H69 appears to be less
striking than originally reported by Mirski et al. (1987).
There are two reasons for this discrepancy. Firstly, we have
expressed our data as AUC's, whereas Mirski et al. expressed
their data in terms of IC50's. We have shown that the AUC
relates most closely to the logarithm of the IC50 (Lam et al.,
1989). Thus, relative resistance values using the IC50 may
appear much greater than when using the AUC. The second
reason is that the MTT assay performed here is quite
different than that used by Mirski et al., as discussed above.
Using the assay as described here we found that H69AR was
cross resistant to the same spectrum of drugs as found by
Mirski et al., with the exception ofmitoxantrone. We did not
find H69AR to be cross resistant to this particular drug,
whereas Mirski et al., found it to be cross resistant. The
reasons for this discrepancy are unclear at the present time.
Sixteen SCLC cell lines were used for comparative chemo-
sensitivity studies. These include lines established from
patients with a spectrum of clinically drug sensitive and drug
resistant disease. Only one of these lines (H69AR) had under-
gone in vitro selection for drug resistance. As well, although
all of the cell lines are examples of SCLC, and were treated
as such, they represent a pathologic spectrum, ranging from
one cell line which was difficult to distinguish from an
atypical carcinoid tumour, to one which was difficult to
distinguish from large cell anaplastic carcinoma. From a
clinical, pathological and biological point of view, SCLC is a
heterogeneous disease. We believe that if one is to make
clinically relevant conclusions regarding the spectrum of
clinical drug responsiveness of SCLC cell lines, it is impor-
tant to include a large number of cell lines representative of
the complete pathologic and clinical spectrum of the disease.
The comparative chemosensitivity studies of these SCLC
cell lines reveal some interesting patterns of drug sensitivity
and resistance. In particular, one cell line, NCI-H209, stood
out as the most sensitive to most of the drugs tested, includ-
ing natural products, alkylating agents, and platinum com-
pounds. The cell line H69AR, which had been selected in
adriamycin, was the most resistant to a number of natural
product drugs. Because it is feasible to test multiple drugs,
this assay has the potential to reveal valuable information
regarding the incidence of multidrug resistance in the clinical
setting.
A number of investigators (Batist et al., 1986; Carmichael
et al., 1988; Carney et al., 1983; Ruckdeschel et al., 1987;
Tsai et al., 1989) have found a close correlation between
chemotherapy treatment status and the relative in vitro
chemosensitivity of the cell line derived from that patient. We
found that cell lines established from untreated patients were
more sensitive to nearly all of the drugs than lines established
from treated patients. However, the results were statistically
significant for only two of the drugs, and the differences for
most of the drugs were not striking.
It is not possible on the basis of data presented here to
make any clinical correlations on clinical samples. It would
also be premature to attempt to make any definitions of in
vitro sensitivity and resistance on the basis ofdata from such
a small number of patients. Studies currently in progress of
clinical chemosensitivity testing in haematologic malignancies
should give a definitive answer regarding clinical correlations
using this assay.
In summary, we have shown that the MTT assay can be
applied to in vitro chemosensitivity testing of SCLC lines and
fresh clinical samples. While some technical problems remain,
this assay may have potential applications for predictive
chemosensitivity testing.
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